azhar

studying @demos_network 🐪 | 05’

[Mgoes (bio/acc 🤖💉) @m_goes_distance]

in case you're doubting how brutal the longevity biotech acceleration has been in the first half of 2026

here are a few signals:

- Chai Discovery is reportedly raising $400M at a $3.4B valuation. AI-native biology is starting to command frontier-AI multiples
- Verve Therapeutics triggered a ~$1B acquisition after demonstrating permanent cholesterol reduction via a single gene edit. One treatment. Lifelong effect
- Retro Biosciences dosed the first humans with RTR242. a pill that reactivates the brain's cellular cleanup machinery. Sam Altman's bet on adding 10 healthy years to life. Phase 1 results Q3
- Junevity begins first-in-human trials H2 2026. their platform identified a novel target regulating chronic metabolic dysfunction. a natural GLP-1 alternative with no side effects
- Life Biosciences injected the first ever reverse-aging drug into a human this week. three reprogramming genes delivered directly to aging cells. results by end of 2026
- David Sinclair just announced an oral reprogramming pill entering the $101M XPRIZE. not an injection. a pill you swallow. whole-body biological age reversal

all of these converge in the same 6-month window

this has never happened before in the history of longevity science

the narrative is about to shift permanently

bio/acc

[kerman kohli @kermankohli]

the plot thickens.

behind anthropic’s cute branding for the vibe coders is a seriously dark side imo.

it’s finally becoming more clear to everyone.

[azhar @onchainmaxi]

@kermankohli outperforming our internet coins man

[Citrini @citrini]

I give it a year until we see a new breed of AI native private equity firms that acquire companies just so they can move their workflows from Claude to open source Chinese models and flip them.

[Kian Sadeghi @KianSadeghi5]

Genetic engineering in human embryos is here.

Today, in a world first, @Columbia and @nucleusgenomics announce high-efficiency editing of human embryos.

The study, led by Dr. Dieter Egli's lab at Columbia University, with Nucleus Genomics’ Dr. Nathan Treff as a senior co-author, achieved editing efficiencies of up to 100% at targeted loci. Simultaneously, we showed no detectable editing-induced chromosomal abnormalities and low off-target activity.

In other words, this is the closest we've come to practical, high-precision gene editing in human embryos.

We are also excited to announce we will be funding and participating in the next phase of this research, alongside Columbia and Dr. Egli.

We see ourselves as a natural pathway for eventually bringing technologies like this into clinical care as part of a broader genetics platform — a full "Genetic Optimization" stack.

@nytimes broke the news in what is a historic moment for Genetic Optimization. See story in thread.

[Andrew D. Huberman, Ph.D. @hubermanlab]

The new Huberman Lab episode is out: Peptides: The Science, Uses & Safety | Dr. @AbudBakri

0:00 Abud Bakri
3:33 What are Peptides?, Receptors
6:26 BPC-157, Discovery, Animal Proteins
11:19 BPC-157, Animal Data, Regeneration
12:27 Sponsors: Eight Sleep & Lingo
14:51 BPC-157, Regeneration & Healing, Neurological Effects
19:27 Adverse Events, Clinical Trials & Legality of BPC-157
29:41 GLPs & Compounding Pharmacy; Peptides & Gray Market
35:25 Manufacturing, Compounding Pharmacies, Gray Market, Black Market
41:32 Peptides & Tumor Growth?; Angiogenesis
45:17 Sponsor: AG1
47:01 Pharmaceutical Patents, Clinical Trials for BPC-157, Potential Outcomes
54:19 BPC-157 Healing, Patient Experiences
1:01:22 Physician Counsel, FDA Legality, Malpractice
1:07:25 Pinealon, Epithalon, Discovery; Sleep & Cognitive Performance, Risks
1:18:17 Sponsor: Function
1:19:55 Pineal Age Deterioration, Epithalon, Eye Health
1:29:38 Thymus, Age Shrinkage; Thymosin Alpha-1, Immune Function
1:38:13 TB-500; Pet Health; Thymic Peptide Doses, Thymulin, Zinc
1:49:13 Sponsor: LMNT
1:50:33 GHK-Cu (Copper GHK), Collagen
1:55:32 Illness Recovery, Thymic Score, Tool: Blood Test & Immune Cell Counts
2:04:01 Growth Hormone Secretagogues, Age Decline, Cancer Risk, Insulin
2:15:36 GHK-Cu, Topical Cream, Red Light Therapy
2:20:25 GLPs, Discovery, Physical & Cognitive Long-Term Effects, Fertility
2:33:53 Retatrutide; Drug Patents & Nomenclature
2:39:03 Peptides: Women Reproductive Disorders; TBI, Neurologic Effect; Safe Sources
2:45:34 Zero-Cost Support, YouTube, Spotify & Apple Follow, Reviews & Feedback, Sponsors, Protocols Book, Social Media, Neural Network Newsletter

Includes paid partnerships.

[Bryan Johnson @bryan_johnson]

These numbers are shocking. It's like we got a new frontier AI model but for the body.

Lilly's phase 3 results for retatrutide:

> highest dose lost 28.3% of body weight in 80 wks
> 70 lbs ave
> 45% lost 30% or more of their body weight
> 65% on the top dose no longer clinically obese

Retatrutide is more dynamic than semaglutide and tirzepatide because it targets three receptors (GIP, GLP-1, and glucagon), versus one and two, respectively.

Side effects, on the highest dose (12mg), were higher for retatrutide than tirzepatide (nausea and GI), with an 11.3% drop out rate. The lowest 4mg dose still delivered 19% loss with fewer dropouts than placebo.

[azhar @onchainmaxi]

@WuBlockchain an oracle for chuds

[Wu Blockchain @WuBlockchain]

Pyth Network Suffers Hermes and Core Feed Downtime

Pyth Network reported an outage affecting Pythnet/Hermes, disrupting its core price feeds and sponsored feeds for over four hours. The team said validators are coordinating a restart after identifying the root cause of the issue. The incident may affect DeFi protocols relying on Pyth oracle data for trading, lending, and liquidation operations.

[Cuy Sheffield @cuysheffield]

This is a must read on the necessary stack for the agentic economy

“The company that wins it will not look like a model lab. It will look like a market operator: part exchange, part payments network, part identity provider, part trust infrastructure, part governance platform. In other words, less like OpenAI and more like Visa, Moody's, Stripe, Nasdaq, and ServiceNow fused into a single system for software actors.”

[rinko @mrinko]

solving the oracle problem is one of crypto's grand challenges. right up there with things like the stablecoin trilemma and proof of personhood

today these problems seem near impossible, and maybe they are. but to solve one would mean unlocking a new branch of the tech tree

[Mgoes (bio/acc 🤖💉) @m_goes_distance]

biotech will do more for humanity in the next 18 months than the last 50 years

here is what the next 12-18 months carry:

1. aging becomes reversible - Life Biosciences reports results from the first ever human epigenetic reprogramming trial by end of 2026. if it works the entire category reprices overnight

2. your genome becomes your medical record-consumer grade sequencing is already at $1,100. by 2027 it is a standard intake form

3. personalized gene therapies become real - baby KJ proved a custom CRISPR therapy can be built for one person in 6 months. his doctors are now building the FDA pathway to do it for everyone

4. peptides go fully mainstream - 14 of 19 banned compounds are coming back to legal compounding. the grey market becomes a regulated industry with actual quality standards

5. psychedelics become first line treatment - Compass Pathways is weeks from the first ever FDA approval of a psychedelic drug. depression and PTSD treatment just changed permanently

6. AI designs drugs that work better than anything a human team has ever produced- Isomorphic Labs is pushing AI-designed molecules into human trials right now. results expected this year

7. BCIs move from medical to performance - Merge Labs, Neuralink, Synchron all pointed at the same target. the first healthy person gets an implant for cognitive enhancement and the waitlist forms immediately after

bio/acc

[Y Combinator @ycombinator]

The future of ultrasound is 3D. Lumius is making it fast, accessible, and intelligent — a universal 3D camera for the body.

Congrats on the launch, @treevoo_lumius and @lichenhang1225!

https://t.co/7IzDsljqrf

[azhar @onchainmaxi]

@paulg tf is this tweet

[azhar @onchainmaxi]

@demishassabis @IsomorphicLabs incredibly bullish

[Ansem 🐂🀄️ @blknoiz06]

you are still early to AI

[azhar @onchainmaxi]

@smart wow, congrats

[TBPN @tbpn]

"I do not think a chatbot is the right interface for travel or e-commerce." - @bchesky

"I think the future is not apps. The future is agents, but I don't think they're going to be text-forward. I think they're going to be really rich user interfaces."

"Imagine using iMessage to do everything, when in fact every other app has a unique interface."

"With e-commerce, you want a very rich user interface. It would be agentic. You can have a conversation with it, but the point is that it has to be more visual."

[Hims House @himshouse]

$HIMS

THE PEPTIDE SUPPLY CHAIN --- JUST 5 COMPANIES IN CHINA CONTROL ~90% OF THE AMINO ACIDS 🤯

@mansizzzzle: "Before any peptide is produced, you need its API, which stands for 'active pharmaceutical ingredient', and right now China supplies most of the world's API"

"The top 5 companies in China control around 90% of the protected amino acids, which is essentially the raw building block of a peptide."

"You can't attach raw amino acids to each other. That's a very volatile and chaotic process... The error rate tends to compound every time you attach one amino acid to the other. So for example, BPC-157 sits at around 15 amino acids, and it tends to come out correct around 75% of the time. And Semaglutide (Ozempic) sits at 31 amino acids, and that comes out correct around 50% of the time."

"This is why China wins: because they have this at massive scale to compensate for these efficiency issues."

"CordenPharma in Colorado is the largest in the US. They have around 10,000 liter of SPPS reactor capacity."

"But in China there's a company called WuXi AppTec, which has 100,000 liters of capacity... more than 10x larger than *the largest* synthesis plant here in the United States."

[azhar @onchainmaxi]

@ogx5125 @illscience not enough people are talking about this. pretty fascinating.